Do you remember the leukemia and lymphoma research presented at ASH? Test your knowledge now and see how you rank!
Feb 22, 2024
A curated eBook featuring 65th ASH Annual Meeting leukemia and lymphoma-focused studies, findings, and expert opinions.
Research from ASH 2023 showed standard treatment options lack efficacy for patients who are positive for the TP53 mutation with AML.
Patients reporting increased fatigue have a higher hazard of death compared with those who did not after adjusting for covariates.
Treatment that includes acalabrutinib can improve progression-free survival in treatment-naïve patients with chronic lymphocytic leukemia.
A sandwich treatment model that includes acalabrutinib and rituximab in combination with R-DHAOx chemotherapy shows encouraging results in phase 2 trial.
The following is a summary of "Benefit of Allogeneic Transplant in 1st Complete Remission in...
The following is a summary of "Autologous Transplant (auto-HCT) Is Associated with Improved...
The following is a summary of "Addition of Acalabrutinib to Lenalidomide and Rituximab Induces...
With over 275 exhibitors, the 65th ASH Annual Meeting exhibit hall is not to be missed!
Sign up today for the virtual 2023 ASH Foundation Run/Walk!
Make the most of your attendance at the 65th ASH annual meeting by utilizing these helpful resources to plan your schedule and stay informed!